TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02523976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Second-generation tyrosine kinase inhibitor
Study: NCT02959437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB057643
Description: INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
Study: NCT00864032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg twice daily
Study: NCT01059760

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fasting First
Description: 28±4 hours of water-only fasting followed by 28±4 hours fed

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Fed First
Description: 28± 4 hours fed followed by 28± 4 hours of fasting
Study: NCT01736228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL
Description: two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
Study: NCT02046980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gufoni

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vibration

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study: NCT01388816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
Study: NCT01898026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muffins
Description: Samples of muffins, with or without the addition of PGX fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Hot Breakfast Cereal
Description: Samples of hot breakfast cereal without the addition of soluble fibre blend

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hot Breakfast Cereal
Description: Samples of hot breakfast cereal without the addition of soluble fibre blend
Study: NCT03750175

Intervention type: OTHER
Intervention: Plasma circulating DNA analysis
Description: Clinical utility of ctDNA analysis for treatment decision
Study: NCT00417989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiniMed Paradigm REAL-Time System
Description: Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
Study: NCT03169530

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: \~15 gm daily of beer, wine, or spirits for \~6 years
Study: NCT01032200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT03145519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vasofix Certo Catheter
Description: Placement of IV-catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OptiVein Catheter
Description: Placement of IV-catheter
Study: NCT00672100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 5 ml Ropivacaine via interscalene injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 10 ml Ropivacaine via interscalene injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Initial Bolus 20 ml Ropivacaine via interscalene injection
Study: NCT02567786

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with CPB

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery with CPB

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte
Study: NCT01772381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Long acting corticosteroid
Study: NCT03550014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Back Only
Description: The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Back+Hip
Description: The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
Study: NCT01033097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 5 mg
Description: 5 mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 5 mg
Description: 5 mg placebo oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 25 mg
Description: 25 mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 25 mg
Description: 25 mg placebo oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 100 mg
Description: 100 mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 100 mg
Description: 100 mg placebo oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 4 mg
Description: 4 mg oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 1mg
Description: 1 mg oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 1mg
Description: 1 mg placebo oral
Study: NCT01339156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3914
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Study: NCT01374971

Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol (CZP)
Description: CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic synovial tissue biopsy
Description: Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
Study: NCT03468387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary realignment
Description: Endoscopic realignment of rupture urethra over a urethral catheter
Study: NCT01388816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
Study: NCT02087163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Movement Enhancement Technique
Description: Conventional Orthodontic treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligner
Description: Orthodontic treatment with Clear Aligner
Study: NCT02232893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Study: NCT02468765

Intervention type: OTHER
Intervention: Neuropsychological and emotional evaluation with monitoring
Description: Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests

Intervention type: OTHER
Intervention: Neuropsychological and emotional evaluation with monitoring
Description: Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests

Intervention type: OTHER
Intervention: Neuropsychological and emotional evaluation with monitoring
Description: Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Study: NCT04325750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TECAR Therapy
Description: The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: simulated TECAR Therapy (machine off)
Study: NCT03182868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
Study: NCT02523976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Study: NCT00576069

Intervention type: DRUG
Intervention: budesonide/formoterol
Description: 2 inhalations 2X/daily in treated arm/group. No placebo group

Intervention type: DRUG
Intervention: fluticasone/salmeterol
Description: fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group

Intervention type: DRUG
Intervention: mometasone/formoterol
Description: 200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group

Intervention type: DRUG
Intervention: Prednisone
Description: 0-15 mg daily as needed
Study: NCT05984953

Intervention type: DRUG
Intervention: statin
Description: 40 mg of rosuvastatin daily for 8-12 weeks

Intervention type: DRUG
Intervention: statin
Description: 40 mg of rosuvastatin daily for 8-12 weeks

Intervention type: DRUG
Intervention: evolocumab
Description: 140 mg evolocumab every 2 weeks (26 weeks)
Study: NCT04514848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI Multiplex HIV-1/2 Syphilis AB test
Description: For the detection of antibodies to syphilis and HIV

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo Rapid TP/HIV test
Description: For the detection of antibodies to syphilis and HIV
Study: NCT02363946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic
Study: NCT03468387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapubic cystostomy
Description: Percutaneous cystostomy catheter will be inserted under sonographic guidance
Study: NCT02511847

Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: 1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course.
Study: NCT02523976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study: NCT02298153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: atezolizumab: administered intravenously (IV) every three weeks (q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat: Oral daily dosing
Study: NCT03727919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training
Description: In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training
Description: In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
Study: NCT03542942

Intervention type: OTHER
Group type: OTHER
Intervention: treatment with EXIT-target volume
Description: exclusion of the unaffected part of the uterus out of the treatment field
Study: NCT03158038

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Vaccine
Description: A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
Study: NCT01644071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cipralex
Description: one time 10 mg, tablet
Study: NCT02187198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study: NCT01136057

Intervention type: BIOLOGICAL
Intervention: Collection of Anti-Influenza A Immune Plasma
Study: NCT00572936

Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost
Description: prostaglandin

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide
Description: carbonic anhydrase inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Timolol
Description: beta blocker
Study: NCT00771342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
Study: NCT00703586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.